FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology. Described is an immunomodulator for application in inhibition of immunoresistant gene expression relating to the tumor, with the immonomodulator being sdRNA which enables to suppress expression of RD1, with sdRNA comprising a guide strand and a passenger strand, with the guide strand being 19-25 nucleotides in length and the passenger strand being 10-19 nucleotides in length, with sdRNA comprising a double-stranded and a single-stranded region, with the single-stranded region comprising 5-9 phosphorothioate modifications, with the sdRNA being chemically modified including at least one 2’-O-methyl modification or a 2’-Fluoro modification and with the guide strand comprising a sequence complementary to the one chosen from SEQ ID NO: 281-300. Provided is also a composition comprisind said immunomodulator and a method for producing same. Besides, provided is a method for treating an individual suffering from a proliferative disease or an infectious disease, with the method comprising a stage at which the immunogenic composition is administrated to the individual.
EFFECT: invention enables inhibition of suppression of immune response through reducing expression of one or several genes involved in immunosuppression mechanism.
22 cl, 7 dwg, 2 tbl, 11 ex
